おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Fortis Therapeutics
company
About
Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies against CD46.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $18M
- Industries
- Biotechnology,Therapeutics
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Fortis Therapeutics is immuno-oncology biotech focused on developing new antibody-drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$58M
Fortis Therapeutics has raised a total of
$58M
in funding over 2 rounds. Their latest funding was raised on
Mar 29, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 29, 2021 | Series A | $40M | 1 | — | — | Detail |
| Sep 27, 2016 | Series A | $18M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Fortis Therapeutics is funded by 1 investors.
Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lilly Asia Ventures
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
